**Opinion**
Volume 15:05, 2025

Journal of Bioprocessing & Biotechniques

ISSN: 2155-9821

Open Access

# Optimizing mRNA Therapeutic Bioprocessing for Scalability

**Thomas E. Müller***

*Department of Industrial Biotechnology, RWTH Aachen University, Aachen, Germany*

## Introduction

The manufacturing of mRNA therapeutics has undergone significant advancements, driven by the critical need for scalability and cost-effectiveness. Optimizing bioprocesses is paramount to achieving these goals, with a particular focus on enhancing the production of the essential plasmid DNA (pDNA) template, improving the efficiency of in vitro transcription (IVT), and developing robust downstream purification methods [1]. This intricate process involves meticulous fine-tuning of fermentation parameters, enzyme concentrations, and buffer compositions to maximize mRNA yield and purity while simultaneously minimizing the presence of impurities that could compromise therapeutic efficacy and safety [1]. Innovative approaches, such as continuous processing and novel purification techniques, are actively being explored to facilitate industrial-scale manufacturing [1].

At the heart of high-quality mRNA production lies the optimization of the in vitro transcription (IVT) process. This optimization encompasses the judicious selection of the appropriate polymerase, the precise tuning of nucleotide concentrations, and the careful control of reaction conditions, including temperature and pH [2]. A critical aspect of this process is the implementation of strategies to minimize the formation of double-stranded RNA (dsRNA), a prevalent impurity that can significantly impact therapeutic effectiveness [2]. Achieving this requires careful selection of transcription templates and optimized IVT reaction kinetics [2].

Downstream processing for mRNA purification presents substantial challenges in meeting the stringent purity and yield requirements for therapeutic applications. Chromatographic methods, such as anion-exchange and hydrophobic interaction chromatography, are commonly employed in this stage [3]. However, the optimization of these steps is crucial for effectively removing residual reagents, dsRNA, and truncated mRNA species [3]. Consequently, the development of more efficient and scalable purification strategies, including tangential flow filtration and novel affinity-based methods, remains an active area of research [3].

Plasmid DNA (pDNA) serves as the indispensable template for mRNA synthesis, making the optimization of its fermentation and purification a prerequisite for efficient mRNA production [4]. This upstream phase involves selecting appropriate expression hosts, optimizing media composition, and precisely controlling fermentation parameters like aeration and agitation [4]. The subsequent efficient downstream processing of pDNA, which typically includes alkaline lysis and purification steps, is vital for obtaining high yields of supercoiled pDNA with minimal contamination [4].

The delivery of mRNA therapeutics conventionally relies on lipid nanoparticles (LNPs). However, achieving efficient and safe delivery necessitates the optimization of LNP formulation and manufacturing processes [5]. This optimization involves precise control over particle size, encapsulation efficiency, and surface charge [5]. The scale-up of LNP production, employing methods such as microfluidics or tangential flow filtration, is essential for therapeutic applications and demands careful process control to ensure consistent batch-to-batch quality [5].

Ensuring the safety and efficacy of mRNA therapeutics hinges on the implementation of rigorous quality control and analytical methods [6]. These methods are essential for quantifying mRNA integrity, assessing the levels of impurities such as dsRNA and residual DNA, and thoroughly characterizing the LNP formulation [6]. The comprehensive product characterization relies heavily on advanced analytical techniques, including liquid chromatography-mass spectrometry (LC-MS), RNA sequencing, and dynamic light scattering (DLS) [6].

Process intensification strategies, with continuous manufacturing at the forefront, offer significant promise for enhancing the efficiency and scalability of mRNA production [7]. The application of continuous flow reactors for IVT and continuous chromatography for purification can lead to a reduced manufacturing footprint, improved product consistency, and potentially lower production costs [7]. Nevertheless, challenges persist in seamlessly integrating these continuous steps and maintaining consistent product quality throughout the entire manufacturing process [7].

The regulatory landscape governing mRNA therapeutics is dynamic and continuously evolving [8]. Consequently, bioprocess optimization efforts must rigorously adhere to regulatory guidelines, ensuring that manufacturing processes are not only well-characterized but also tightly controlled [8]. Demonstrating comparability between different manufacturing processes and ensuring the consistency of the final product are critical prerequisites for regulatory approval, necessitating robust documentation and validation of all process steps [8].

Enzyme engineering plays a pivotal role in elevating the efficiency of mRNA synthesis [9]. By modifying RNA polymerases to enhance their processivity, reduce byproduct formation, and improve thermostability, significant boosts in mRNA yields can be achieved [9]. Similarly, engineering capping enzymes or developing alternative in vitro capping strategies can improve capping efficiency, a factor crucial for mRNA stability and effective translation [9]. This enzymatic approach directly influences the economic viability and scalability of mRNA production [9].

Robust upstream processes, particularly for generating the pDNA template, form the bedrock of mRNA production [10]. This includes optimizing microbial fermentation to achieve high cell densities and efficient plasmid replication, with factors like inducer concentration, temperature, and nutrient feeding strategies being critical [10]. Advances in synthetic biology and metabolic engineering are also being explored to engineer host strains for improved pDNA yield and quality, thereby reducing the downstream processing burden and associated costs [10].

## Description

The manufacturing of mRNA therapeutics requires a multi-faceted approach to bioprocess optimization, beginning with the critical enhancement of plasmid DNA (pDNA) production. This involves carefully selecting appropriate expression hosts, optimizing media composition, and precisely controlling fermentation parameters such as aeration and agitation to achieve high cell densities and efficient plasmid replication [1]. Following fermentation, efficient downstream processing of pDNA, including alkaline lysis and subsequent purification, is vital to obtain high yields of supercoiled pDNA with minimal contamination [1].

The subsequent stage, in vitro transcription (IVT), is central to producing high-quality mRNA. This process necessitates the careful selection of the right polymerase and the optimization of nucleotide concentrations, alongside precise control of reaction conditions like temperature and pH [2]. A key challenge in IVT is minimizing the formation of double-stranded RNA (dsRNA), a common impurity that can affect therapeutic efficacy, which is addressed through careful template selection and optimized reaction kinetics [2].

Downstream processing for mRNA purification presents significant hurdles in achieving the required purity and yield for therapeutic applications [3]. Chromatographic methods, including anion-exchange and hydrophobic interaction chromatography, are commonly employed [3]. However, optimizing these techniques to remove residual reagents, dsRNA, and truncated mRNA species is paramount [3]. The development of more efficient and scalable purification strategies, such as tangential flow filtration and novel affinity-based methods, remains an active research frontier [3].

Lipid nanoparticles (LNPs) are the standard for mRNA delivery, but their effective and safe application depends on optimizing LNP formulation and manufacturing [5]. This optimization involves controlling particle size, encapsulation efficiency, and surface charge [5]. Scaling up LNP production using methods like microfluidics or tangential flow filtration is essential for therapeutic use and requires stringent process control to ensure batch-to-batch consistency [5].

Quality control and analytical methods are indispensable for guaranteeing the safety and efficacy of mRNA therapeutics [6]. These methods are used to quantify mRNA integrity, assess the levels of impurities like dsRNA and residual DNA, and characterize the LNP formulation [6]. Advanced analytical techniques, such as liquid chromatography-mass spectrometry (LC-MS), RNA sequencing, and dynamic light scattering (DLS), are critical for comprehensive product characterization [6].

Process intensification, particularly through continuous manufacturing, holds significant promise for improving the efficiency and scalability of mRNA production [7]. Continuous flow reactors for IVT and continuous chromatography for purification can lead to a smaller manufacturing footprint, enhanced consistency, and potentially reduced costs [7]. However, integrating these continuous steps and maintaining product quality throughout the process remain ongoing challenges [7].

The regulatory landscape for mRNA therapeutics is continuously evolving, making it imperative for bioprocess optimization to align with regulatory guidelines [8]. Manufacturing processes must be well-characterized and controlled, with strong emphasis placed on demonstrating comparability between different manufacturing processes and ensuring the consistency of the final product for regulatory approval [8]. This necessitates robust documentation and validation of all process steps [8].

Enzyme engineering plays a vital role in enhancing the efficiency of mRNA synthesis [9]. Modifying RNA polymerases to improve their processivity, reduce byproduct formation, and increase thermostability can significantly boost mRNA yields [9]. Similarly, engineering capping enzymes or developing alternative in vitro capping strategies can enhance capping efficiency, which is crucial for mRNA stability and translation [9]. This approach directly impacts the economics and scalability of mRNA production [9].

Advances in bioprocess engineering for mRNA therapeutics production are crucial for scalability and cost-effectiveness [1]. Key areas include enhancing pDNA production, improving IVT efficiency, and developing robust downstream purification methods [1]. Fine-tuning fermentation parameters, enzyme concentrations, and buffer compositions are essential for maximizing mRNA yield and purity while minimizing impurities [1]. Innovative approaches like continuous processing are also being explored for industrial-scale manufacturing [1].

Strategies for high-yield production and purification of plasmid DNA are foundational [4]. Optimizing pDNA fermentation and purification is a prerequisite for efficient mRNA production, involving the selection of appropriate expression hosts, media composition, and fermentation parameters [4]. Efficient downstream processing of pDNA is vital to obtain high yields of supercoiled pDNA with minimal contamination [4].

## Conclusion

The production of mRNA therapeutics is critically dependent on optimizing several key bioprocess stages. This includes enhancing plasmid DNA (pDNA) production through improved fermentation and purification, optimizing in vitro transcription (IVT) by selecting appropriate polymerases and reaction conditions to minimize impurities like double-stranded RNA (dsRNA), and developing efficient downstream purification methods using chromatography and other techniques. Furthermore, the formulation and manufacturing of lipid nanoparticles (LNPs) for effective mRNA delivery, along with robust quality control and analytical strategies, are essential. Process intensification through continuous manufacturing and advancements in enzyme engineering offer avenues for increased efficiency and scalability. Regulatory considerations and adherence to guidelines are paramount throughout the entire manufacturing process. Ultimately, these integrated efforts aim to achieve scalable, cost-effective, and safe production of mRNA therapeutics.

## Acknowledgement

None.

## Conflict of Interest

None.

## References

1. Florian R. Schmidt, Anja Hofmann, Michael J. Betenbender. "Advances in Bioprocess Engineering for the Manufacturing of mRNA Vaccines and Therapeutics." *Biotechnology Journal* 18 (2023):e2200241.

2. Anja Schwanhäußer, Thomas R. Mertens, Andreas Herrmann. "Optimizing In Vitro Transcription for Messenger RNA Production." *Methods in Molecular Biology* 2546 (2022):201-215.

3. Xianyun Li, Ying Zhang, Shuang Xu. "Downstream Processing Strategies for mRNA Purification: Challenges and Innovations." *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 1235 (2023):123789.

4. Jianjun Zhang, Mei Li, Wenlong Zhang. "Strategies for High-Yield Production and Purification of Plasmid DNA." *Current Pharmaceutical Biotechnology* 22 (2021):573-585.

5. Chenxi Li, Peiwen Tang, Chao Wang. "Lipid Nanoparticles for mRNA Delivery: Formulation and Manufacturing Strategies." *Advanced Drug Delivery Reviews* 196 (2023):114641.

6. Sebastian W. Müller, Julia K. Schneider, Markus F. Schmidt. "Analytical Strategies for mRNA Therapeutic Quality Control." *Analytical Chemistry* 94 (2022):13765-13779.

7. Hongyan Liu, Zhiqiang Wang, Jianjun Li. "Process Intensification for mRNA Manufacturing: Towards Continuous Bioprocessing." *Journal of Pharmaceutical Innovation* 18 (2023):1-12.

8. Elizabeth A. M. Johnson, Robert S. Chen, Sarah L. Brown. "Regulatory Considerations for mRNA Therapeutic Manufacturing." *Drug Discovery Today* 27 (2022):1708-1714.

9. Huihui Li, Xiaojing Wang, Li Zhang. "Enzymatic Strategies for Enhanced mRNA Synthesis." *Current Opinion in Chemical Engineering* 40 (2023):100785.

10. Fei Yang, Jingwen Wang, Rui Zhang. "Microbial Fermentation for Plasmid DNA Production: Current Status and Future Prospects." *Biotechnology Advances* 60 (2022):107010.

**How to cite this article:** Müller, Thomas E.. "Optimizing mRNA Therapeutic Bioprocessing for Scalability." *J Bioprocess Biotech* 15 (2025):699.

***Address for Correspondence:** Thomas, E. Müller, Department of Industrial Biotechnology, RWTH Aachen University, Aachen, Germany, E-mail: t.mueller@rwtachen.de



**Received:** 01-Sep-2025, Manuscript No. jbpbt-25-178523; **Editor assigned:** 03-Sep-2025, PreQC No. P-178523; **Reviewed:** 17-Sep-2025, QC No. Q-178523; **Revised:** 22-Sep-2025, Manuscript No. R-178523; **Published:** 29-Sep-2025, DOI: 10.37421/2155-9821.2025.15.699